Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Minneapolis, MN, April 26, 2017 -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today announced that the Company will be attending the Heart Rhythm Society’s 38th Annual Scientific Sessions May 10-13 at McCormick Place in Chicago, Illinois.
During the event, BioSig management will provide updates on their PURE EP(TM) System, a novel cardiac signal acquisition and display system, including pre-clinical data obtained with the PURE EP System presented in the form of a poster presentation entitled, “Use of Terminal Unipolar Electrogram Current of Injury as a Novel Marker to Estimate Contact: An Acute Canine Study”.
The event will feature more than 900 of the world’s most noted experts in cardiac rhythm management and will serve as faculty for more than 250 educational sessions covering topic areas including pacing, defibrillation, clinical arrhythmia management, ablation, pharmacology, genetics, basic science, health policy, and many other topics. Attendees will be immersed in the global community of professionals dedicated to improving the care of patients with heart rhythm disorders.
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary technology platform designed to improve the $4 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market.
The PURE EP System is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance and CE Mark for the PURE EP System.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates.. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Relations: Lora Mikolaitis BioSig Technologies, Inc. [email protected] 310.948.7200
